Back

Featured Topics

Behind The Science
Breast Cancer
Cancer Immunotherapy
Hematology
Lung Cancer
Manufacturing
Multiple Sclerosis
Oncology
Ophthalmology
Partnering
Respiratory Health
Rheumatology
About Us Contact Us Leadership Awards & Recognition Investors Suppliers Compliance
  • Twitter
  • Facebook
  • LinkedIn

No Longer a Skin Deep Conversation


Read More Stories
May 28, 2014

Jennifer Low, M.D., Ph.D.

Senior Group Medical Director, Product Development
Genentech


It’s 2014, and we’re talking about advanced skin cancer in terms of personalized medicines, targeted combinations and immunotherapies. What we shouldn’t forget is that as little as five years ago there were no approved targeted medicines for skin cancer, especially in metastatic melanoma, the deadliest form of the disease.

At the ASCO meeting this week, we will be talking about the latest scientific breakthroughs in metastatic melanoma. But the more important conversation is the one that has evolved between a person diagnosed with this disease and his or her doctor about treatment options.

In the early 1960s, there wasn’t a medicine specifically for metastatic melanoma, so doctors had to remove the tumor with surgery. Forty years later, there were two types of medicines for metastatic melanoma, including chemotherapy, but there was still a need for more options. By the early 2000’s, some of the advances seen in other cancers were being realized in skin cancer. There are now personalized medicines, immunotherapies, chemotherapy and more than 100 clinical trials of investigational medicines being conducted.

Within the past five years, advanced melanoma has gone from a disease with limited options and poor prognosis to one where there are now multiple options. We’ve begun to shift the way the disease is thought about and treated, and improve upon how long people could live with the disease. But more options are still needed and there is much we can do.

Fortunately, scientific breakthroughs are quickly translating into new treatment advances for cancer. While this is good news for those affected by and those who treat this terrible disease, it also raises important questions – and some of the most pressing questions today are being tackled in skin cancer. These range from combining immunotherapies with personalized medicines, to sequencing treatments, to designing clinical trials that can produce data quickly enough to keep pace with the rapidly changing treatment environment.


Metastatic melanoma is still a potentially deadly disease, but the outlook has gotten better in the last five years than in the past 50.


I predict we’ll continue to see diseases like advanced melanoma be a “proving ground” for cutting-edge treatment approaches across oncology. Imagine if, in the next five years, we are able to determine the exact regimen of medicines that will treat an individual’s tumor, making medicine truly “personalized”.

What do you think we’ll see in the next five years? Tweet your prediction with the hashtag #Next50 to join the conversation.

  • Biography Down arrow

    Jennifer Low, M.D., Ph.D, is currently a Senior Group Medical Director in Product Development Oncology and a Development Review Committee Chair, providing strategic direction and overseeing clinical development of oncology pipeline medicines. Jennifer joined Genentech at the end of 2006, leading development of a skin cancer medicine from its first-in-human study through U.S. FDA approval.

     

    Prior to joining Genentech, she was a Senior Investigator in the Investigational Drug Branch of the Cancer Therapy Evaluation Program at the National Cancer Institute (NCI). She was also a senior staff physician in the Medical Oncology Branch of the Center of Cancer Research, NCI, where she was an attending in the breast cancer clinics at NIH and the National Naval Medical Center. She completed her undergraduate degree from Caltech, medical and doctoral degrees from Georgetown and trained in internal medicine at UC Davis and medical oncology at the NCI.


Tags:

  • ASCO 2014

Read More Stories

Read about breakthrough science, the everyday people who make it happen, and the patients we serve.

  • Now Hiring
  • Find A Job
  • Professional Areas
  • Diversity & Inclusion
  • Chief Diversity Officer
  • Fostering Belonging
  • Health Equity
  • Advancing Inclusive Research
  • Transforming Society
  • Our 2021 Diversity & Inclusion Report
  • Our Work in Action
  • Kindergarten to Careers
  • For Scientists
  • Our Scientists
  • Publications
  • Oncology
  • Immunology
  • Neuroscience
  • Metabolism
  • Infectious Disease
  • Ophthalmology
  • For Patients
  • Our Medicines
  • Financial Support
  • Genentech Patient Foundation
  • Understanding Insurance
  • Medicine Information Support
  • Clinical Trial Information
  • Advancing Inclusive Research
  • Our Approach to Pricing
  • Patient Advocacy
  • Create With Us
  • Disease Education
  • For Medical Professionals
  • Our Medicines & Products
  • Our Pipeline
  • Medical Resources
  • Clinical Trial Information
  • Sunshine Act Compliance
  • Product Security
  • For Partners
  • Our Approach
  • What We Are Looking For
  • Partner With Us
  • Our Stories
  • For Media
  • News Features
  • Press Releases
  • Statements
  • Company Information
  • Sign Up For News Alerts
  • For Good
  • Giving
  • Diversity & Inclusion
  • Sustainability
  • About Us
  • Leadership
  • Policy & Advocacy
  • Our Focus on Oncology
  • Awards & Recognition
  • Investors
  • Suppliers
  • Our Approach to Pricing
  • CA Transparency in Supply
  • Compliance Overview
  • Contact Us
  • Call Us
  • Email Us
  • Visit us
  • Submit a Medical Inquiry
  • Submit a Media Inquiry
  • —
  • Privacy Policy
  • Terms & Conditions
  • Accessibility
© 2023 Genentech, Inc. All rights reserved. This site is intended for US residents only.